{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"75600","upperLimit":"344000","value":"133000"},{"groupId":"OG001","lowerLimit":"123000","upperLimit":"181000","value":"152000"},{"groupId":"OG002","lowerLimit":"108000","upperLimit":"108000","value":"108000"},{"groupId":"OG003","lowerLimit":"98300","upperLimit":"110000","value":"104000"},{"groupId":"OG004","lowerLimit":"183000","upperLimit":"214000","value":"199000"},{"groupId":"OG005","lowerLimit":"76000","upperLimit":"180000","value":"82200"},{"groupId":"OG006","lowerLimit":"46800","upperLimit":"102000","value":"74400"},{"groupId":"OG007","lowerLimit":"41200","upperLimit":"106000","value":"83700"},{"groupId":"OG008","lowerLimit":"138000","upperLimit":"306000","value":"203000"},{"groupId":"OG009","lowerLimit":"9390","upperLimit":"22200","value":"12800"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"4"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"4"},{"groupId":"OG009","value":"8"}],"units":"Participants"}],"title":"Cycle 1 day 1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"135000","upperLimit":"271000","value":"185000"},{"groupId":"OG001","lowerLimit":"309000","upperLimit":"361000","value":"348000"},{"groupId":"OG002","lowerLimit":"345000","upperLimit":"345000","value":"345000"},{"groupId":"OG003","lowerLimit":"191000","upperLimit":"1360000","value":"405000"},{"groupId":"OG004","lowerLimit":"216000","upperLimit":"376000","value":"296000"},{"groupId":"OG005","lowerLimit":"21000","upperLimit":"62300","value":"34800"},{"groupId":"OG006","lowerLimit":"446000","upperLimit":"455000","value":"450000"},{"groupId":"OG007","lowerLimit":"227000","upperLimit":"619000","value":"272000"},{"groupId":"OG008","lowerLimit":"65000","upperLimit":"252000","value":"153000"},{"groupId":"OG009","lowerLimit":"16600","upperLimit":"28600","value":"25700"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"4"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"4"},{"groupId":"OG009","value":"3"}],"units":"Participants"}],"title":"Cycle 1 day 8"},{"categories":[{"measurements":[{"groupId":"OG009","lowerLimit":"3530","upperLimit":"95400","value":"14600"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"6"}],"units":"Participants"}],"title":"Cycle 1 day 15"}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"4"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"4"},{"groupId":"OG009","value":"8"}],"units":"Participants"}],"description":"Plasma concentrations of AMG 176 were determined using a validated assay. Noncompartmental analysis was performed for estimation of PK parameters. Concentrations below the LLOQ of 5.00 ng/mL were set to zero before data analysis.","dispersionType":"Full Range","groups":[{"description":"Participants with MM received AMG 176 Dose E in cycle 1 week 1, then received Dose F QW. AMG 176 was administered as an IV infusion in a 4-week cycle.","id":"OG000","title":"Part 1B Cohort 1 (MM): AMG 176 Dose E Then Dose F QW"},{"description":"Participants with MM received AMG 176 Dose E in cycle 1 week 1, then received Dose G QW. AMG 176 was administered as an IV infusion in a 4-week cycle.","id":"OG001","title":"Part 1B Cohort 2 (MM): AMG 176 Dose E Then Dose G QW"},{"description":"Participants with MM received AMG 176 Dose E in cycle 1 week 1, then received Dose H QW. AMG 176 was administered as an IV infusion in a 4-week cycle.","id":"OG002","title":"Part 1B Cohort 3 (MM): AMG 176 Dose E Then Dose H QW"},{"description":"Participants with MM received AMG 176 Dose E in cycle 1 week 1, then received Dose I QW. AMG 176 was administered as an IV infusion in a 4-week cycle.","id":"OG003","title":"Part 1B Cohort 4 (MM): AMG 176 Dose E Then Dose I QW"},{"description":"Japanese participants with AML received AMG 176 Dose E in cycle 1 week 1, then received Dose F QW. AMG 176 was administered as an IV infusion in a 4-week cycle.","id":"OG004","title":"Part 3 Cohort 4 (Japanese Participants With AML): AMG 176 Dose E Then Dose F QW"},{"description":"Participants with AML received AMG 176 Dose E QW. AMG 176 was administered as an IV infusion in a 4-week cycle.","id":"OG005","title":"Part 3B Cohort 1 (AML): AMG 176 Dose E QW"},{"description":"Participants with AML received AMG 176 Dose E in cycle 1 week 1, then received Dose F QW. AMG 176 was administered as an IV infusion in a 4-week cycle.","id":"OG006","title":"Part 3B Cohort 2 (AML): AMG 176 Dose E Then Dose F QW"},{"description":"Participants with AML received AMG 176 Dose E in cycle 1 week 1, then received Dose G QW. AMG 176 was administered as an IV infusion in a 4-week cycle.","id":"OG007","title":"Part 3B Cohort 3 (AML): AMG 176 Dose E Then Dose G QW"},{"description":"Japanese participants with AML received AMG 176 Dose E QW. AMG 176 was administered as an IV infusion in a 4-week cycle.","id":"OG008","title":"Part 3C Cohort 1 (Japanese Participants With AML): AMG 176 Dose E QW"},{"description":"Participants with AML received AMG 176 Dose D QW. AMG 176 was administered as an IV infusion in a 4-week cycle. They also received 200 mg itraconazole QD for 7 days in week 1.","id":"OG009","title":"Part 3D Cohort 1 (AML): AMG 176 Dose D QW + Itraconazole"}],"paramType":"MEDIAN","populationDescription":"The PK analysis set included all participants who had received at least 1 dose of AMG 176 and had at least 1 PK sample collected. AUC0-168 was pre-specified in Parts 1B, 3 (Cohort 4), 3B, 3C, and 3D and participants with data available at each time point are presented.","reportingStatus":"POSTED","timeFrame":"Parts 1B, 3B, 3C, and 3 (cohort 4): Cycle 1 day 1 pre, EOI, 1, 2, 3, 5, and 7 hrs EOI, cycle 1 day 8 pre, EOI; Part 3d also cycle 1 day 15 pre and EOI","title":"AUC From Time 0 to 168 Hours (AUC0-168) of AMG 176 (Parts 1B, 3 [Cohort 4], 3B, 3C, and 3D)","type":"PRIMARY","unitOfMeasure":"hour*ng/mL"}